Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

601 questions in 75 reviews · Schizophrenia

current versions

No studies 601 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE Hospital admission ‐ not reported · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
FLUPHENAZINE DECANOATE vs PLACEBO Clinically significant change in global state ‐ not reported · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
FLUPHENAZINE DECANOATE vs PLACEBO Hospital admission ‐ not reported · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS Death ‐ not reported · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
'As required' medication vs regular timed medication Mental state: important change in mental state · seriously mentally ill people in hospital 'As required' medication regimens for seriously mentally ill people in hospital (2015) · Cochrane	no estimate extracted	NR	No studies
'As required' medication vs regular timed medication Behaviour: important change in behaviour · seriously mentally ill people in hospital 'As required' medication regimens for seriously mentally ill people in hospital (2015) · Cochrane	no estimate extracted	NR	No studies
'As required' medication vs regular timed medication Behaviour: aggression · seriously mentally ill people in hospital 'As required' medication regimens for seriously mentally ill people in hospital (2015) · Cochrane	no estimate extracted	NR	No studies
'As required' medication vs regular timed medication Dosage: important difference in dose used · seriously mentally ill people in hospital 'As required' medication regimens for seriously mentally ill people in hospital (2015) · Cochrane	no estimate extracted	NR	No studies
'As required' medication vs regular timed medication Adverse events: important adverse events · seriously mentally ill people in hospital 'As required' medication regimens for seriously mentally ill people in hospital (2015) · Cochrane	no estimate extracted	NR	No studies
'As required' medication vs regular timed medication Satisfaction with care: important change in satisfaction with care · seriously mentally ill people in hospital 'As required' medication regimens for seriously mentally ill people in hospital (2015) · Cochrane	no estimate extracted	NR	No studies
'As required' medication vs regular timed medication Cost: important change in cost · seriously mentally ill people in hospital 'As required' medication regimens for seriously mentally ill people in hospital (2015) · Cochrane	no estimate extracted	NR	No studies
PERPHENAZINE vs ANY ANTIPSYCHOTICS Death ‐ not reported · patients with schizophrenia Perphenazine for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
PERPHENAZINE vs ANY ANTIPSYCHOTICS Economic outcomes ‐ not reported · patients with schizophrenia Perphenazine for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
PERPHENAZINE vs ANY ANTIPSYCHOTICS Service use and hospitalisation: admission ‐ not reported · patients with schizophrenia Perphenazine for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
PERPHENAZINE vs PLACEBO Adverse events: death ‐ not reported · patients with schizophrenia Perphenazine for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
PERPHENAZINE vs PLACEBO Adverse events: serious adverse events ‐ not reported · patients with schizophrenia Perphenazine for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
PERPHENAZINE vs PLACEBO Economic outcomes ‐ not reported · patients with schizophrenia Perphenazine for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
PERPHENAZINE vs PLACEBO Service use and hospitalisation: admission ‐ not reported · patients with schizophrenia Perphenazine for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
Lithium vs antipsychotics Kidney dysfunction outcome not available in any study · participants with schizophrenia Lithium for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
Lithium vs antipsychotics Thyroid dysfunction outcome not available in any study · participants with schizophrenia Lithium for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
Adjunctive lithium + antipsychotics vs placebo/no adjunctive treatment + antipsychotics Kidney dysfunction outcome not available in any study · participants with schizophrenia Lithium for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
Adjunctive lithium + antipsychotics vs placebo/no adjunctive treatment + antipsychotics Thyroid dysfunction outcome not available in any study · participants with schizophrenia Lithium for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
Lithium as sole treatment vs placebo Kidney dysfunction outcome not available in any study · participants with schizophrenia Lithium for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
Lithium as sole treatment vs placebo Thyroid dysfunction outcome not available in any study · participants with schizophrenia Lithium for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
SUPPORTIVE THERAPY vs FAMILY THERAPY Satisfaction with treatment ‐ not reported · patients with schizophrenia Supportive therapy for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
SUPPORTIVE THERAPY vs FAMILY THERAPY Quality of life ‐ not reported · patients with schizophrenia Supportive therapy for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
SUPPORTIVE THERAPY vs PSYCHOEDUCATION Global state: Relapse ‐ not reported · patients with schizophrenia Supportive therapy for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
SUPPORTIVE THERAPY vs PSYCHOEDUCATION General functioning ‐ not reported · patients with schizophrenia Supportive therapy for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
SUPPORTIVE THERAPY vs PSYCHOEDUCATION Satisfaction with treatment ‐ not reported · patients with schizophrenia Supportive therapy for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
TEMPOROPARIETAL TMS vs STANDARD TREATMENT Mental state ‐ not reported · people with schizophrenia Transcranial magnetic stimulation (TMS) for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
TEMPOROPARIETAL TMS vs STANDARD TREATMENT Cognitive state ‐ not reported · people with schizophrenia Transcranial magnetic stimulation (TMS) for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
TEMPOROPARIETAL TMS vs STANDARD TREATMENT Adverse effects: general or specific ‐ not reported · people with schizophrenia Transcranial magnetic stimulation (TMS) for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
TEMPOROPARIETAL TMS vs STANDARD TREATMENT Satisfaction with care ‐ not reported · people with schizophrenia Transcranial magnetic stimulation (TMS) for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
PREFRONTAL TMS vs SHAM TMS Clinical improvement in global state ‐ not reported · people with schizophrenia Transcranial magnetic stimulation (TMS) for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
PREFRONTAL TMS vs SHAM TMS Satisfaction with care ‐ not reported · people with schizophrenia Transcranial magnetic stimulation (TMS) for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
PREFRONTAL TBS TMS vs SHAM TMS Global state score ‐ not reported · people with schizophrenia Transcranial magnetic stimulation (TMS) for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
PREFRONTAL TBS TMS vs SHAM TMS Satisfaction with care ‐ not reported · people with schizophrenia Transcranial magnetic stimulation (TMS) for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
TEMPOROPARIETAL TMS vs SHAM TMS Satisfaction with care ‐ not reported · people with schizophrenia Transcranial magnetic stimulation (TMS) for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
TEMPOROPARIETAL TMS vs STANDARD TREATMENT Global state score ‐ not reported · people with schizophrenia Transcranial magnetic stimulation (TMS) for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
Adjunct cognitive behavioural therapy vs adjunct supportive psychotherapy Global state: Clinically significant improvement · patients with delusional disorder Treatments for delusional disorder (2015) · Cochrane	no estimate extracted	NR	No studies
Adjunct cognitive behavioural therapy vs adjunct supportive psychotherapy Mental state: Delusions ‐ clinically significant improvement · patients with delusional disorder Treatments for delusional disorder (2015) · Cochrane	no estimate extracted	NR	No studies
Adjunct cognitive behavioural therapy vs adjunct supportive psychotherapy Service use: Admission · patients with delusional disorder Treatments for delusional disorder (2015) · Cochrane	no estimate extracted	NR	No studies
ZUCLOPENTHIXOL ACETATE vs PLACEBO Clinically significant response on psychotic symptoms ‐ as defined by each of the studies. · people with schizophrenia Zuclopenthixol versus placebo for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
ZUCLOPENTHIXOL ACETATE vs PLACEBO Other adverse effects, general and specific · people with schizophrenia Zuclopenthixol versus placebo for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
ZUCLOPENTHIXOL ACETATE vs PLACEBO Leaving the study early · people with schizophrenia Zuclopenthixol versus placebo for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
ZUCLOPENTHIXOL ACETATE vs PLACEBO Average change in quality of life/satisfaction · people with schizophrenia Zuclopenthixol versus placebo for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
ZUCLOPENTHIXOL ACETATE vs PLACEBO Significant change in quality of life/satisfaction ‐ as defined by each of the studies · people with schizophrenia Zuclopenthixol versus placebo for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
ZUCLOPENTHIXOL DECANOATE vs PLACEBO Clinically significant response on global state · people with schizophrenia Zuclopenthixol versus placebo for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
ZUCLOPENTHIXOL DECANOATE vs PLACEBO Relapse as defined by the studies · people with schizophrenia Zuclopenthixol versus placebo for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
ZUCLOPENTHIXOL DECANOATE vs PLACEBO Clinically significant response on psychotic symptoms ‐ as defined by each of the studies · people with schizophrenia Zuclopenthixol versus placebo for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies